Organon & Co. OGN

OGN Company Overview

Organon & Co. is a global healthcare company focused primarily on women’s health, biosimilars, and established medicines. The company was formed in 2021 through a spin-off from Merck & Co., Inc. (known as MSD outside the United States) and is publicly traded on the New York Stock Exchange under the ticker OGN. Organon operates in the pharmaceutical industry, with core revenue generated from branded and generic-like mature therapies, contraceptive products, fertility treatments, and biosimilar medicines. Its portfolio spans prescription therapeutics and reproductive health products used across gynecology, fertility, cardiovascular, respiratory, dermatology, and non-opioid pain management categories.

The company’s primary strategic positioning centers on women’s health, where it markets products for contraception and fertility while leveraging a global commercial infrastructure inherited from its former parent company. Key products include Nexplanon, a long-acting reversible contraceptive implant, and fertility therapies marketed through its reproductive medicine portfolio. Organon also derives substantial revenue from mature legacy medicines and biosimilars distributed across both developed and emerging markets. The company evolved from the historical Organon pharmaceutical brand originally founded in the Netherlands in 1923, later integrated into Schering-Plough and subsequently Merck following Merck’s acquisition of Schering-Plough in 2009. The modern Organon & Co. structure was established through the 2021 spin-off transaction detailed in SEC filings and investor materials.